DOCSLIB.ORG

Whole-Genome Sequencing Identifies Genomic Heterogeneity at a Nucleotide and Chromosomal Level in Bladder Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Whole-Genome Sequencing Identifies Genomic Heterogeneity at a Nucleotide and Chromosomal Level in Bladder Cancer Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer Carl D. Morrisona,1,2, Pengyuan Liub,1, Anna Woloszynska-Readc, Jianmin Zhangd, Wei Luoc, Maochun Qine, Wiam Bsharaf, Jeffrey M. Conroya, Linda Sabatinif, Peter Vedellb, Donghai Xiongb, Song Liue, Jianmin Wange, He Shend, Yinwei Lid, Angela R. Omilianf, Annette Hillf, Karen Headf, Khurshid Gurug, Dimiter Kunnevh, Robert Leache, Kevin H. Enge, Christopher Darlaka, Christopher Hoeflicha, Srividya Veerankia, Sean Glennd, Ming Youb, Steven C. Pruitth, Candace S. Johnsonc, and Donald L. Trumpi aCenter for Personalized Medicine and Departments of cPharmacology and Therapeutics, dCancer Genetics, eBiostatistics and Bioinformatics, fPathology, gUrology, hMolecular and Cellular Biology, and iMedicine, Roswell Park Cancer Institute, Buffalo, NY 14263; and bDepartment of Physiology and the Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53226 Edited* by Carlo M. Croce, The Ohio State University, Columbus, OH, and approved January 2, 2014 (received for review July 22, 2013) Using complete genome analysis, we sequenced five bladder tumors earlier studies in melanoma (13) and medulloblastoma (14), ev- accrued from patients with muscle-invasive transitional cell carcinoma idence of the association of TP53 mutations with specific copy of the urinary bladder (TCC-UB) and identified a spectrum of genomic number alterations, referred to as chromothripsis, was noted. The aberrations. In three tumors, complex genotype changes were noted. study in medulloblastoma (14) was particularly intriguing in that All three had tumor protein p53 mutations and a relatively large identification of a molecular subclass with TP53 mutations was number of single-nucleotide variants (SNVs; average of 11.2 per associated with chromothripsis and a more aggressive clinical megabase), structural variants (SVs; average of 46), or both. This group outcome was noted. Chromothripsis, or the shattering of two or was best characterized by chromothripsis and the presence of more chromosomes and their reassembly into derivative chro- subclonal populations of neoplastic cells or intratumoral mutational mosomes, is different from other types of genomic instability, heterogeneity. Here, we provide evidence that the process of chromo- which tend to occur on a genome-wide basis (15, 16). Chromo- thripsis in TCC-UB is mediated by nonhomologous end-joining using thripsis is different in that it includes one to three alternating kilobase, rather than megabase, fragments of DNA, which we refer to copy number states across the derivative chromosome, an asso- “ ” as stitchers, to repair this process. We postulate that a potential uni- ciation with changes in heterozygosity, and numerous genomic fying theme among tumors with the more complex genotype group is – rearrangements in localized chromosomal regions likely occurring a defective replication licensing complex. A second group (two bladder in condensed chromosomes (15). There is evidence to suggest tumors) had no chromothripsis, and a simpler genotype, WT tumor that the primary mechanism of reassembly of the derivative protein p53, had relatively few SNVs (average of 5.9 per megabase) chromosome in chromothripsis is nonhomologous end-joining and only a single SV. There was no evidence of a subclonal population (NHEJ) (14). With the advent of next-generation sequencing of neoplastic cells. In this group, we used a preclinical model of bladder (NGS) allowing for detailed genomic analysis, chromothripsis carcinoma cell lines to study a unique SV (translocation and amplifica- tion) of the gene glutamate receptor ionotropic N-methyl D-aspertate as a potential new therapeutic target in bladder cancer. Significance next-generation sequencing | tumor heterogeneity | GRIN2A | replication Genetic alterations are frequently observed in bladder cancer. In this study, we demonstrate that bladder tumors can be ransitional cell carcinoma arising in the urinary bladder (TCC- classified into two different types based on the spectrum of TUB) is a frequent cause of morbidity and mortality, and among genetic diversity they confer. In one class of tumors, we ob- patients in the United States, it is one of the most costly cancers to served tumor protein p53 mutations and a large number of treat (1, 2). The traditional somatic genetic basis of TCC-UB is single-nucleotide and structural variants. Another characteristic a distinct division of low-grade papillary tumors from high-grade of this group was chromosome shattering, known as chromo- invasive tumors. Low-grade papillary superficial tumors are gener- thripsis, and mutational heterogeneity. The other two bladder ally characterized by constitutive activation of the receptor tyrosine tumors did not show these profound genetic aberrations, but kinase–Ras pathway, and they have activating mutations in the we found a novel translocation and amplification of the gene , HRAS and fibroblast growth factor receptor 3 (FGFR3) genes glutamate receptor ionotropic N-methyl D-aspertate a poten- (3–6). In contrast, high-grade invasive TCC-UB is characterized tially druggable target. Advancements in bladder cancer by alterations in the tumor protein p53 (TP53) and retino- treatment have been slow. Understanding the genetic land- blastoma 1 (RB1) pathways. These genes normally regulate the scape of bladder cancer may therefore help to identify new cell cycle by interacting with the Ras–mitogen-activated protein therapeutic targets and bolster management of this disease. kinase signal transduction pathway (7, 8). Both low-grade papillary Author contributions: C.D.M., W.B., K.G., M.Y., C.S.J., and D.L.T. designed research; C.D.M., and high-grade invasive tumors frequently have loss of chromosome J.Z., W.L., J.M.C., L.S., A.R.O., A.H., and K.H. performed research; M.Q., C.D., C.H., and 9. This loss presumably inactivates the p16 geneandisanearly S.V. contributed new reagents/analytic tools; C.D.M., P.L., J.Z., M.Q., J.M.C., P.V., D.X., event in the initiation of TCC-UB (9, 10) S.L., J.W., H.S., Y.L., D.K., R.L., K.H.E., C.D., C.H., S.V., and S.G. analyzed data; and C.D.M., Although TP53, cyclin-dependent kinase inhibitor 2A (p16), RB1, P.L., A.W.-R., J.Z., J.M.C., S.C.P., C.S.J., and D.L.T. wrote the paper. HRAS,andFGFR3 abnormalities have been well described in TCC- The authors declare no conflict of interest. UB, there are limited data on the more complete genomic analysis *This Direct Submission article had a prearranged editor. of TCC-UB (11). A recent study focusing on genome-wide copy 1C.D.M. and P.L. contributed equally to this work. number analysis showed extensive heterogeneity across all sub- 2To whom correspondence should be addressed. E-mail: [email protected]. types of TCC-UB to such an extent that precise molecular This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. groupings were difficult to define (12). In this study, similar to 1073/pnas.1313580111/-/DCSupplemental. E672–E681 | PNAS | Published online January 27, 2014 www.pnas.org/cgi/doi/10.1073/pnas.1313580111 Downloaded by guest on September 27, 2021 has been identified more frequently (17). Additionally, the 100 PNAS PLUS presence of these complex genomic events and their potential 90 SNV/MbNV/Mb Structural Variants TP53mut/p16wt association with TP53 mutations may contribute to a better un- 80 derstanding of cancer, including TCC-UB. 70 Increasing genomic complexity NGS technologies provide other evidence of complex genomic 60 TP53mut/p16del heterogeneity, such as the recent identification of subclonal pop- 50 ulations of cells with mutations distinct from the dominant clonal 40 population of cells within one tumor or between a primary, re- 30 – TP53mut/p16del current, or metastatic tumor from one patient (18 20). Importantly, 20 TP53wt/p16wt TP53wt/p16del a recent study in chronic lymphocytic leukemia (CLL) (21) showed 10 how selective pressures on cancer cells, such as chemotherapy, se- 0 lect for these subclonal populations to become the dominant 16933 17802 18698 18195 19685 clone contributing to genomic heterogeneity. It is not yet certain TP53 mutant whether broad measurements of genomic heterogeneity will TP 53/p16 have an impact on molecular classification of cancer, but it is wild type p16 deletion likely that they will significantly contribute to biological differ- Single structural variant Frequent structural variants (SVs) ences, and therefore have an impact on patient outcomes. (SV) Frequent single nucleotide variants To evaluate the spectrum of genomic heterogeneity in TCC- Fewer single nucleotide (SNVs) UB, we performed complete genome sequencing of five high- variants (SNVs) TP53 mutant SI TP53 wild type Chromothripsis involving multiple grade muscle-invasive tumors and matching germ-line blood ( Chromothripsis absent chromosomes Appendix, Table S1), and validated a subset of our findings in No evidence of subclonal Subclonal populations identified in 2 more than 300 bladder cancer specimens. Our overall results populations of 3 showed a great deal of genomic heterogeneity at either extreme of a spectrum of genomic complexity. Fig. 1. Number of SNVs per megabase (Mb) of DNA and total number of validated SVs for each of five patients with muscle-invasive TCC-UB used for Results whole-genome sequencing. Three of the five tumors (cases 18195, 18698, and 19685) had many more SVs and SNVs than the other two tumors and Overview of Somatic Alterations Reveals Heterogeneity
Load more

Recommended publications
  • Prioritization and Evaluation of Depression Candidate Genes by Combining Multidimensional Data Resources
    Prioritization and Evaluation of Depression Candidate Genes by Combining Multidimensional Data Resources Chung-Feng Kao1, Yu-Sheng Fang2, Zhongming Zhao3, Po-Hsiu Kuo1,2,4* 1 Department of Public Health and Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, 2 Institute of Clinical Medicine, School of Medicine, National Cheng-Kung University, Tainan, Taiwan, 3 Departments of Biomedical Informatics and Psychiatry, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America, 4 Research Center for Genes, Environment and Human Health, National Taiwan University, Taipei, Taiwan Abstract Background: Large scale and individual genetic studies have suggested numerous susceptible genes for depression in the past decade without conclusive results. There is a strong need to review and integrate multi-dimensional data for follow up validation. The present study aimed to apply prioritization procedures to build-up an evidence-based candidate genes dataset for depression. Methods: Depression candidate genes were collected in human and animal studies across various data resources. Each gene was scored according to its magnitude of evidence related to depression and was multiplied by a source-specific weight to form a combined score measure. All genes were evaluated through a prioritization system to obtain an optimal weight matrix to rank their relative importance with depression using the combined scores. The resulting candidate gene list for depression (DEPgenes) was further evaluated by a genome-wide association (GWA) dataset and microarray gene expression in human tissues. Results: A total of 5,055 candidate genes (4,850 genes from human and 387 genes from animal studies with 182 being overlapped) were included from seven data sources.
    [Show full text]
  • Novel Gene Fusions in Glioblastoma Tumor Tissue and Matched Patient Plasma
    cancers Article Novel Gene Fusions in Glioblastoma Tumor Tissue and Matched Patient Plasma 1, 1, 1 1 1 Lan Wang y, Anudeep Yekula y, Koushik Muralidharan , Julia L. Small , Zachary S. Rosh , Keiko M. Kang 1,2, Bob S. Carter 1,* and Leonora Balaj 1,* 1 Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, USA; [email protected] (L.W.); [email protected] (A.Y.); [email protected] (K.M.); [email protected] (J.L.S.); [email protected] (Z.S.R.); [email protected] (K.M.K.) 2 School of Medicine, University of California San Diego, San Diego, CA 92092, USA * Correspondence: [email protected] (B.S.C.); [email protected] (L.B.) These authors contributed equally. y Received: 11 March 2020; Accepted: 7 May 2020; Published: 13 May 2020 Abstract: Sequencing studies have provided novel insights into the heterogeneous molecular landscape of glioblastoma (GBM), unveiling a subset of patients with gene fusions. Tissue biopsy is highly invasive, limited by sampling frequency and incompletely representative of intra-tumor heterogeneity. Extracellular vesicle-based liquid biopsy provides a minimally invasive alternative to diagnose and monitor tumor-specific molecular aberrations in patient biofluids. Here, we used targeted RNA sequencing to screen GBM tissue and the matched plasma of patients (n = 9) for RNA fusion transcripts. We identified two novel fusion transcripts in GBM tissue and five novel fusions in the matched plasma of GBM patients. The fusion transcripts FGFR3-TACC3 and VTI1A-TCF7L2 were detected in both tissue and matched plasma.
    [Show full text]
  • Evidence for Differential Alternative Splicing in Blood of Young Boys With
    Stamova et al. Molecular Autism 2013, 4:30 http://www.molecularautism.com/content/4/1/30 RESEARCH Open Access Evidence for differential alternative splicing in blood of young boys with autism spectrum disorders Boryana S Stamova1,2,5*, Yingfang Tian1,2,4, Christine W Nordahl1,3, Mark D Shen1,3, Sally Rogers1,3, David G Amaral1,3 and Frank R Sharp1,2 Abstract Background: Since RNA expression differences have been reported in autism spectrum disorder (ASD) for blood and brain, and differential alternative splicing (DAS) has been reported in ASD brains, we determined if there was DAS in blood mRNA of ASD subjects compared to typically developing (TD) controls, as well as in ASD subgroups related to cerebral volume. Methods: RNA from blood was processed on whole genome exon arrays for 2-4–year-old ASD and TD boys. An ANCOVA with age and batch as covariates was used to predict DAS for ALL ASD (n=30), ASD with normal total cerebral volumes (NTCV), and ASD with large total cerebral volumes (LTCV) compared to TD controls (n=20). Results: A total of 53 genes were predicted to have DAS for ALL ASD versus TD, 169 genes for ASD_NTCV versus TD, 1 gene for ASD_LTCV versus TD, and 27 genes for ASD_LTCV versus ASD_NTCV. These differences were significant at P <0.05 after false discovery rate corrections for multiple comparisons (FDR <5% false positives). A number of the genes predicted to have DAS in ASD are known to regulate DAS (SFPQ, SRPK1, SRSF11, SRSF2IP, FUS, LSM14A). In addition, a number of genes with predicted DAS are involved in pathways implicated in previous ASD studies, such as ROS monocyte/macrophage, Natural Killer Cell, mTOR, and NGF signaling.
    [Show full text]
  • Primate Specific Retrotransposons, Svas, in the Evolution of Networks That Alter Brain Function
    Title: Primate specific retrotransposons, SVAs, in the evolution of networks that alter brain function. Olga Vasieva1*, Sultan Cetiner1, Abigail Savage2, Gerald G. Schumann3, Vivien J Bubb2, John P Quinn2*, 1 Institute of Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, U.K 2 Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK 3 Division of Medical Biotechnology, Paul-Ehrlich-Institut, Langen, D-63225 Germany *. Corresponding author Olga Vasieva: Institute of Integrative Biology, Department of Comparative genomics, University of Liverpool, Liverpool, L69 7ZB, [email protected] ; Tel: (+44) 151 795 4456; FAX:(+44) 151 795 4406 John Quinn: Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK, [email protected]; Tel: (+44) 151 794 5498. Key words: SVA, trans-mobilisation, behaviour, brain, evolution, psychiatric disorders 1 Abstract The hominid-specific non-LTR retrotransposon termed SINE–VNTR–Alu (SVA) is the youngest of the transposable elements in the human genome. The propagation of the most ancient SVA type A took place about 13.5 Myrs ago, and the youngest SVA types appeared in the human genome after the chimpanzee divergence. Functional enrichment analysis of genes associated with SVA insertions demonstrated their strong link to multiple ontological categories attributed to brain function and the disorders. SVA types that expanded their presence in the human genome at different stages of hominoid life history were also associated with progressively evolving behavioural features that indicated a potential impact of SVA propagation on a cognitive ability of a modern human.
    [Show full text]
  • Multiple Myeloma Risk Variant at 7P15.3 Creates an IRF4-Binding Site and Interferes with CDCA7L Expression
    ARTICLE Received 7 Jul 2016 | Accepted 19 Oct 2016 | Published 24 Nov 2016 DOI: 10.1038/ncomms13656 OPEN Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression Ni Li1,2, David C. Johnson2, Niels Weinhold3,4, James B. Studd1, Giulia Orlando1, Fabio Mirabella2, Jonathan S. Mitchell1, Tobias Meissner5, Martin Kaiser2, Hartmut Goldschmidt4,6, Kari Hemminki7,8, Gareth J. Morgan3 & Richard S. Houlston1,2 Genome-wide association studies have identified several risk loci for multiple myeloma (MM); however, the mechanisms by which they influence MM are unknown. Here by using genetic association data and functional characterization, we demonstrate that rs4487645 G4T, the most highly associated variant (P ¼ 5.30 Â 10 À 25), resides in an enhancer element 47 kb upstream of the transcription start site of c-Myc-interacting CDCA7L. The G-risk allele, associated with increased CDCA7L expression (P ¼ 1.95 Â 10 À 36), increases IRF4 binding and the enhancer interacts with the CDCA7L promoter. We show that suppression of CDCA7L limits MM proliferation through apoptosis, and increased CDCA7L expression is associated with adverse patient survival. These findings implicate IRF4-mediated CDCA7L expression in MM biology and indicate how germline variation might confer susceptibility to MM. 1 Division of Genetics and Epidemiology, The Institute of Cancer Research, Surrey SM2 5NG, UK. 2 Division of Molecular Pathology, The Institute of Cancer Research, Surrey SM2 5NG, UK. 3 Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA. 4 Department of Internal Medicine V, University of Heidelberg, 69117 Heidelberg, Germany.
    [Show full text]
  • WO 2014/135655 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/135655 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/EP2014/054384 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 6 March 2014 (06.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13305253.0 6 March 2013 (06.03.2013) EP (84) Designated States (unless otherwise indicated, for every (71) Applicants: INSTITUT CURIE [FR/FR]; 26 rue d'Ulm, kind of regional protection available): ARIPO (BW, GH, F-75248 Paris cedex 05 (FR). CENTRE NATIONAL DE GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, LA RECHERCHE SCIENTIFIQUE [FR/FR]; 3 rue UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Michel Ange, F-75016 Paris (FR).
    [Show full text]
  • WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/079361 Al 25 April 2019 (25.04.2019) W 1P O PCT (51) International Patent Classification: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, C12Q 1/68 (2018.01) A61P 31/18 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, C12Q 1/70 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US2018/056167 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 16 October 2018 (16. 10.2018) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 62/573,025 16 October 2017 (16. 10.2017) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ΓΕ , IS, IT, LT, LU, LV, (71) Applicant: MASSACHUSETTS INSTITUTE OF MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TECHNOLOGY [US/US]; 77 Massachusetts Avenue, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Cambridge, Massachusetts 02139 (US).
    [Show full text]
  • CPTC-CDK1-1 (CAB079974) Immunohistochemistry
    CPTC-CDK1-1 (CAB079974) Uniprot ID: P06493 Protein name: CDK1_HUMAN Full name: Cyclin-dependent kinase 1 Tissue specificity: Isoform 2 is found in breast cancer tissues. Function: Plays a key role in the control of the eukaryotic cell cycle by modulating the centrosome cycle as well as mitotic onset; promotes G2-M transition, and regulates G1 progress and G1-S transition via association with multiple interphase cyclins. Required in higher cells for entry into S-phase and mitosis. Phosphorylates PARVA/actopaxin, APC, AMPH, APC, BARD1, Bcl-xL/BCL2L1, BRCA2, CALD1, CASP8, CDC7, CDC20, CDC25A, CDC25C, CC2D1A, CENPA, CSNK2 proteins/CKII, FZR1/CDH1, CDK7, CEBPB, CHAMP1, DMD/dystrophin, EEF1 proteins/EF-1, EZH2, KIF11/EG5, EGFR, FANCG, FOS, GFAP, GOLGA2/GM130, GRASP1, UBE2A/hHR6A, HIST1H1 proteins/histone H1, HMGA1, HIVEP3/KRC, LMNA, LMNB, LMNC, LBR, LATS1, MAP1B, MAP4, MARCKS, MCM2, MCM4, MKLP1, MYB, NEFH, NFIC, NPC/nuclear pore complex, PITPNM1/NIR2, NPM1, NCL, NUCKS1, NPM1/numatrin, ORC1, PRKAR2A, EEF1E1/p18, EIF3F/p47, p53/TP53, NONO/p54NRB, PAPOLA, PLEC/plectin, RB1, TPPP, UL40/R2, RAB4A, RAP1GAP, RCC1, RPS6KB1/S6K1, KHDRBS1/SAM68, ESPL1, SKI, BIRC5/survivin, STIP1, TEX14, beta-tubulins, MAPT/TAU, NEDD1, VIM/vimentin, TK1, FOXO1, RUNX1/AML1, SAMHD1, SIRT2 and RUNX2. CDK1/CDC2-cyclin-B controls pronuclear union in interphase fertilized eggs. Essential for early stages of embryonic development. During G2 and early mitosis, CDC25A/B/C-mediated dephosphorylation activates CDK1/cyclin complexes which phosphorylate several substrates that trigger at least centrosome separation, Golgi dynamics, nuclear envelope breakdown and chromosome condensation. Once chromosomes are condensed and aligned at the metaphase plate, CDK1 activity is switched off by WEE1- and PKMYT1-mediated phosphorylation to allow sister chromatid separation, chromosome decondensation, reformation of the nuclear envelope and cytokinesis.
    [Show full text]
  • This Thesis Has Been Submitted in Fulfilment of the Requirements for a Postgraduate Degree (E.G
    This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use: This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author. The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author. When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given. Investigation into the role of LSH ATPase in chromatin remodelling Alina Gukova Doctor of Philosophy – University of Edinburgh – 2020 ABSTRACT Chromatin remodelling is a crucial nuclear process affecting replication, transcription and repair. Global reduction of DNA methylation is observed in Immunodeficiency-Centromeric Instability-Facial Anomaly (ICF) syndrome. Several proteins were found to be mutated in patients diagnosed with ICF, among them are LSH and CDCA7. LSH is a chromatin remodeller bearing homology to the members of Sf2 remodelling family. A point mutation in its ATPase lobe was identified in ICF. CDCA7 is a zinc finger protein that was recently found to be crucial for nucleosome remodelling activity of LSH. Several point mutations in its zinc finger domain were described in ICF patients. In vitro and in vivo studies have shown that LSH-/- phenotype demonstrates reduction of global DNA methylation, implying that chromatin remodelling LSH functions may be required for the efficient methyltransferase activity, linking this finding to ICF phenotype.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.873,482 B2 Stefanon Et Al
    US007873482B2 (12) United States Patent (10) Patent No.: US 7.873,482 B2 Stefanon et al. (45) Date of Patent: Jan. 18, 2011 (54) DIAGNOSTIC SYSTEM FOR SELECTING 6,358,546 B1 3/2002 Bebiak et al. NUTRITION AND PHARMACOLOGICAL 6,493,641 B1 12/2002 Singh et al. PRODUCTS FOR ANIMALS 6,537,213 B2 3/2003 Dodds (76) Inventors: Bruno Stefanon, via Zilli, 51/A/3, Martignacco (IT) 33035: W. Jean Dodds, 938 Stanford St., Santa Monica, (Continued) CA (US) 90403 FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 WO WO99-67642 A2 12/1999 U.S.C. 154(b) by 158 days. (21)21) Appl. NoNo.: 12/316,8249 (Continued) (65) Prior Publication Data Swanson, et al., “Nutritional Genomics: Implication for Companion Animals'. The American Society for Nutritional Sciences, (2003).J. US 2010/O15301.6 A1 Jun. 17, 2010 Nutr. 133:3033-3040 (18 pages). (51) Int. Cl. (Continued) G06F 9/00 (2006.01) (52) U.S. Cl. ........................................................ 702/19 Primary Examiner—Edward Raymond (58) Field of Classification Search ................... 702/19 (74) Attorney, Agent, or Firm Greenberg Traurig, LLP 702/23, 182–185 See application file for complete search history. (57) ABSTRACT (56) References Cited An analysis of the profile of a non-human animal comprises: U.S. PATENT DOCUMENTS a) providing a genotypic database to the species of the non 3,995,019 A 1 1/1976 Jerome human animal Subject or a selected group of the species; b) 5,691,157 A 1 1/1997 Gong et al.
    [Show full text]
  • Computational Analysis and Polymorphism Study of Tumor Suppressor Candidate Gene-3 for Non Syndromic Autosomal Recessive Mental Retardation
    Naveed et al., J Appl Bioinforma Comput Biol 2016, 5:2 DOI: 10.4172/2329-9533.1000127 Journal of Applied Bioinformatics & Computational Biology Research Article a SciTechnol journal social, practical adaptive skills and conceptual, originating before 18 Computational Analysis and years [1] and intellectual functioning (I.Q below 70%). It is observed that 1- 3% of general population is affected with MR [2]. Because large Polymorphism study of Tumor numbers of X-linked MR genes are involved in mental retardation which gives ratio between mentally retarded males and females which Suppressor Candidate Gene-3 seem to be quite high at 1.4-:1 to 1.6:1 [3]. Intellectual disability has a very diverse etiology [4]. The causes of ID that affect the development for Non Syndromic Autosomal and functioning of CNS prenatally or postnatally can involve both Recessive Mental Retardation genetic and environmental factors [5]. Muhammad Naveed*, Syeda Khushbakht Kazmi, Fiza Anwar, Prenatal causes of mental retardation include congenital Fatima Arshad, Tehreem Zafar Dar and Muddassar Zafar infections such as cytomegalovirus, toxoplasmosis, syphilis, rubella, herpes and human immunodeficiency virus; prolonged maternal fever in the first trimester; disclosure to alcohol or anticonvulsants; Abstract and untreated maternal phenylketonuria (PKU). Complications of prematurity especially in exceptionally low-birth-weight infants or Mental Retardation (MR) is regarded as a neuronal malfunction certain postnatal exposure can lead to mental retardation/ID [6]. characterized by a low Intellectual Quotient (IQ). To date, few genes (GRIK2, TUSC3, TRAPPC9, TECR, ST3GAL3, MED23, MAN1B1, Genetic causes of MD include genomic disorders, chromosome NSUN1 PRSS12, CRBN, CC2D1A) for autosomal-recessive non structural abnormalities, monogenic diseases and chromosome syndromic MR (NS-ARMR) have been identified and established aneusomies.
    [Show full text]
  • Genome-Wide DNA Methylation Profiles in Community Members Exposed to the World Trade Center Disaster
    International Journal of Environmental Research and Public Health Article Genome-Wide DNA Methylation Profiles in Community Members Exposed to the World Trade Center Disaster Alan A. Arslan 1,2,3,* , Stephanie Tuminello 2, Lei Yang 2, Yian Zhang 2, Nedim Durmus 4, Matija Snuderl 5, Adriana Heguy 5,6, Anne Zeleniuch-Jacquotte 2,3, Yongzhao Shao 2,3 and Joan Reibman 4 1 Department of Obstetrics and Gynecology, New York University Langone Health, New York, NY 10016, USA 2 Department of Population Health, New York University Langone Health, New York, NY 10016, USA; [email protected] (S.T.); [email protected] (L.Y.); [email protected] (Y.Z.); [email protected] (A.Z.-J.); [email protected] (Y.S.) 3 NYU Perlmutter Comprehensive Cancer Center, New York, NY 10016, USA 4 Department of Medicine, New York University Langone Health, New York, NY 10016, USA; [email protected] (N.D.); [email protected] (J.R.) 5 Department of Pathology, New York University Langone Health, New York, NY 10016, USA; [email protected] (M.S.); [email protected] (A.H.) 6 NYU Langone’s Genome Technology Center, New York, NY 10016, USA * Correspondence: [email protected] Received: 30 June 2020; Accepted: 25 July 2020; Published: 30 July 2020 Abstract: The primary goal of this pilot study was to assess feasibility of studies among local community members to address the hypothesis that complex exposures to the World Trade Center (WTC) dust and fumes resulted in long-term epigenetic changes. We enrolled 18 WTC-exposed cancer-free women from the WTC Environmental Health Center (WTC EHC) who agreed to donate blood samples during their standard clinical visits.
    [Show full text]